Introduction
============

Systemic sclerosis (SSc; scleroderma) is a disorder characterized by fibrosis of the skin and visceral organs. The pathogenesis of this disease is complex and remains incompletely understood. Nevertheless, autoantibodies represent a serologic hallmark of the disease and have proven value as diagnostic and prognostic biomarkers. Indeed, up to 95% of SSc patients \[[@B1]\] have circulating autoantibodies directed against one or more autoantigens, including topoisomerase I (formerly called Scl-70), centromere proteins (CENPs), RNA polymerase III, and the PM/Scl complex, also known as the human exosome \[[@B2]\]. In SSc, the major disease-related autoantibodies tend to be mutually exclusive \[[@B3]\], suggesting unique pathways for the induction of the B-cell response in this condition. Evidence supporting this concept is extensive, given data indicating that each autoantibody is associated with specific demographic, clinical, genetic, and prognostic features \[[@B4],[@B5]\]. In addition, a growing knowledge of the role of SSc autoantibodies in the pathogenesis of the disease is helping to gain a better understanding of potential novel modes of therapy \[[@B6]-[@B9]\].

Two main types of SS-A/Ro antibodies have been described in SSc. One is directed at a 60-kDa protein known as SS-A/Ro60, which is part of a small cytoplasmic ribonucleoprotein (scRNP) multiprotein complex. Another, which often coexists with the former SS-A/Ro60 antibodies, is directed against a 52-kDa (Ro52) protein that is not normally part of the scRNP complex but is an E3 ubiquity ligase and a member of the tripartite motif (TRIM) family of proteins known as TRIM21 \[[@B10]\]; hence, the preferred terminology of Ro52/TRIM21 is used in this report. The association of Ro60 antibodies with autoimmune conditions is well established, particularly in systemic lupus erythematosus (SLE), subacute cutaneous lupus, and Sjögren syndrome (SjS). Ro52/TRIM21 antibodies have also been reported in a wide variety of autoimmune diseases, although often overlapping with other autoantibodies. However, little is known of their clinical associations, and controversy still exists about whether they have an independent association with autoimmune diseases \[[@B11]\].

The Canadian Scleroderma Research Group (CSRG) is a pan-Canadian, multicenter group of researchers that has, since 2004, recruited more than 1,200 SSc patients. The exact prevalence of SSc in Canada remains unknown, but estimates range from 70 to 440 cases/million \[[@B12],[@B13]\]. Thus, by using the most conservative numbers, the CSRG currently captures up to 8% of all Canadian SSc cases. Detailed demographic, clinical, and serologic data have been obtained on these patients and entered into a central database.

Ro52/TRIM21 antibodies have been identified in 20% of the CSRG cohort, making it the second most common autoantibody in this cohort of SSc patients (Table [1](#T1){ref-type="table"}). Given its high prevalence and the paucity of data on its clinical significance, we undertook this study to determine whether Ro52/TRIM21 antibodies in SSc are associated with distinct disease manifestations in SSc.

###### 

Frequency of selected autoantibodies in the CSRG cohort

                       *n*   \%    Numbers not tested
  -------------------- ----- ----- --------------------
  CENP-B               285   36%   162
  Centromere by IIF    334   35%   2
  CENP-A               275   34%   162
  Ro52/TRIM21          194   20%   0
  RNA polymerase III   144   19%   188
  Topoisomerase I      150   16%   0
  PM/Scl               53    7%    188
  Ro60                 53    6%    0
  U1 RNP               59    6%    0
  Chromatin            44    5%    0
  Sm                   39    4%    0
  SS-B/La              26    3%    0
  Jo-I                 6     1%    0
  Ribosomal P          14    1%    0

*N*= 963. CENP, centromere protein; IIF, indirect immunofluorescence; PM/Scl, polymyositis/scleroderma (exosome) autoantigen; RNP, ribonucleoprotein; Sm, Smith autoantigen; SS-B, Sjögren syndrome antigen B or La.

Methods
=======

Design
------

This is a cross-sectional study of a cohort of SSc patients.

### Study subjects

The study subjects consisted of those enrolled in the Canadian Scleroderma Research Group (CSRG) registry. Patients in this registry are recruited from the practices of rheumatologists across Canada. They must have a diagnosis of SSc confirmed by a rheumatologist, be 18 years of age or older, be fluent in English or French, and be likely to be compliant with study procedures and visits. The patients available for this study were those whose baseline visit was between September 2004 and February 2011.

Certain features of our cohort, including age, female distribution, and proportion of patients with diffuse disease, suggest that the patients included in the CSRG registry are similar to patients included in other large SSc cohorts that have been assembled both in the United States and abroad \[[@B14]\]. Moreover, the cohort includes a mix of patients covering the spectrum of disease severity. The participating rheumatologists in the CSRG include both academic and community rheumatologists, but all have a particular interest in SSc, and thus all are perceived as \"experts.\" They thus recruit patients with more severe disease. Conversely, because the American College of Rheumatology classification criteria for SSc exclude many patients with limited cutaneous disease \[[@B15],[@B16]\], the patients in the CSRG Registry do not have to meet those criteria to be included. Thus, participating rheumatologists also recruit patients with probably milder disease. Finally, the patients in the CSRG Registry are generally recruited as outpatients, and the mean disease duration is approximately 10 years. The cohort probably includes survivor patients with less aggressive disease, but who may have accumulated damage over time. In general, we believe that our patients are representative of the spectrum of SSc seen by the general rheumatology community in Canada.

### Measurement of autoantibodies

Serum was collected from all patients recruited by the CSRG and sent to a central laboratory, Mitogen Advanced Diagnostics Laboratory, at the University of Calgary. Aliquots of sera were stored at -70°C until needed. Anti-Ro52/TRIM21 and other related autoantibodies (topoisomerase I, chromatin, Sm, U1-RNP, ribosomal P, Jo-1, SSA/Ro60, SSB-La) were assayed with an addressable laser-bead immunoassay (ALBIA) by using a commercially available kit (QUANTAPlex ENA 8; INOVA Diagnostics Inc., San Diego, CA, USA) in a Luminex 100 (Luminex Corp., Austin, TX, USA) platform, according to protocols previously described \[[@B17]\]. In addition, anti-CENP antibodies were assessed with indirect immunofluorescence on an HEp-2000 substrate (ImmunoConcepts Inc., Sacramento, CA, USA), and antibodies to RNA polymerase III were detected with ELISA (INOVA Diagnostics) \[[@B17]\], as were antibodies to PM/Scl (PM1 alpha; Dr. Fooke Laboratorien GmbH, Neuss, Germany) \[[@B18]\]. CENP-B ELISA (recombinant full-length CENP-B), and CENP-A ELISA (Dr. Fooke Laboratorien GmbH) were performed according to the manufacturer\'s AI-Line instructions for use, as previously described \[[@B19]\].

### Study measures

Patients recruited into the Registry undergo an extensive medical evaluation with standardized reporting of history, physical evaluation, and laboratory investigations. Demographic information regarding age, sex, and ethnicity is collected by patient self-report. Disease duration determined from the onset of the first non-Raynaud disease manifestation is recorded by the study physician. Skin involvement is assessed by using the modified Rodnan skin score \[[@B20]\], a widely used clinical assessment in which the examining rheumatologist records the degree of skin thickening, ranging from 0 (no involvement) to 3 (severe thickening) in 17 areas (total score range, 0 to 51), and patients are classified into limited and diffuse cutaneous subsets, based on the definition of Leroy *et al.*\[[@B21]\]. Joint examinations are performed by a rheumatologist by using the simplified 28 swollen and tender joint count \[[@B22]\]. History of inflammatory myositis, thrombosis, scleroderma renal crisis, and overlap syndrome was recorded by the study physician. For the purposes of this study, overlap syndrome was defined as a patient with SSc and SLE, SjS, rheumatoid arthritis, polymyositis/dermatomyositis, and/or mixed connective tissue disease.

To assess gastrointestinal involvement, patients answered yes/no to a series of 14 questions concerning appetite loss, difficulty swallowing, regurgitation of acid, nocturnal choking, heartburn, early satiety, abdominal bloating, nausea and vomiting, constipation, diarrhea, need for antibiotics for diarrhea, greasy stools, fecal incontinence, and need for parenteral nutrition.

The presence of interstitial lung disease was determined by using a clinical decision rule that was recently published \[[@B23]\]. This algorithm relies on physical examination (presence of typical \"Velcro-like crackles\" indicative of interstitial lung disease on lung auscultation), chest radiograph, and high-resolution computed tomography (HRCT). Interstitial lung disease is considered present if an HRCT lung study interpreted by an experienced radiologist shows interstitial lung disease or, in the case in which no HRCT was performed, if a chest radiograph is reported as showing either increased interstitial markings (not thought to be due to congestive heart failure) or fibrosis, and/or if a study physician reports the presence of typical Velcro-like crackles on physical examination.

Systolic pulmonary artery pressure (SPAP) is measured by using the Doppler flow measurement of the tricuspid regurgitant jet on echocardiography. Pulmonary hypertension (PH) was defined as an estimated systolic SPAP ≥ 45 mm Hg (an estimate that correlates strongly with right-heart catheter studies \[[@B24]\]).

Disease severity is assessed by using physician and patient global assessments of disease severity recorded on a numeric rating scale ranging from 0, representing no disease, to 10, representing most-severe disease. Disease severity also is measured by using a modified Medsger Scleroderma Disease Severity Scale \[[@B25],[@B26]\]. The scale assesses disease severity in nine organ systems: general health, peripheral vascular, skin, joint/tendon, muscle, gastrointestinal tract, lungs, heart, and kidneys. Each organ is scored separately from 0 to 4, depending on whether no, mild, moderate, severe, or end-stage involvement is present. For the purposes of this study, the worst category was scored for each system, and results of any investigation not requested by the physician, and therefore missing, were considered \"normal.\" Scoring methods for general, peripheral vascular, skin, joint/tendon, lung, and kidney systems were identical to those proposed in the scale. Some adaptations were made to the other organ systems. To assign a score for the skeletal muscle system, physicians were asked to rate patients\' muscle strength in five different areas of the body (neck flexors, as well as upper and lower proximal extremities, right and left) by using the British Medical Research Council scale. A severity score was then assigned depending on the total number of 5s, 4s, 3s, 2s, 1s, and 0s for a given patient. The HAQ-DI was used to assess the patient\'s use of ambulation aids needed to assign the worst severity level for the skeletal muscle system (that is, level 4, end stage).

To score the gastrointestinal system, in addition to an abnormal esophagogram, abnormal esophageal manometry, or abnormal small-bowel series, patients reporting difficulty swallowing, acid taste in their mouth, choking at night, burning sensation, feeling of being full shortly after eating, or taking gastroprotective or promotility agents were also given a score of 1 for mild. In addition to malabsorption syndrome and episodes of pseudo-obstruction, patients with an abnormal hydrogen breath test were given a score of 3 for severe.

To score the heart system, electrocardiogram results, percentage left ventricular ejection fraction values, presence of conduction abnormalities, distended neck veins, and arrhythmia diagnosed by a physician were used.

Statistical analysis
--------------------

Descriptive statistics were used to summarize the baseline characteristics of the patients. χ^2^tests, Yates χ^2^tests, Fisher Exact tests, and Mann-Whitney *U*tests were used, as appropriate. *P*values \< 0.05 were considered statistically significant. A sensitivity analysis was performed in the subset of patients who met the 1980 American College of Rheumatology preliminary classification criteria \[[@B27]\], of which 852 (89%) were found. All of the results were similar. Thus, the results of the whole cohort are presented here.

All statistical analyses were performed with SAS v.9.2 (SAS Institute, San Diego, CA, USA).

Ethical considerations
----------------------

Ethics committee approval for the CSRG data collection protocol was obtained at McGill University (Montreal, Ontario, Canada) and at all participating study sites. All subjects provided informed written consent to participate in the data-collection protocol.

Results
=======

This study included 963 SSc patients with complete serologic data on anti-Ro52/TRIM21 antibodies. Baseline characteristics of the study cohort are presented in Table [2](#T2){ref-type="table"}. Mean age was 54.25 (± 12.04) years; 87% were female; 85% were White; mean disease duration (since the onset of the first non-Raynaud disease manifestation) was 11.04 (± 9.47) years; and 59% had limited, 37% had diffuse, and 3% had no skin involvement.

###### 

Baseline characteristics of the study cohort, as a group and according to anti-Ro52/TRIM21 antibody status

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Whole group\   Anti-Ro52/TRIM21 antibody positive (*n*= 194)   Anti-Ro52/TRIM21 antibody negative (*n*= 769)   Odds ratio (95% CI) and *P*values (Anti-Ro52/TRIM21 positive vs negative)                                        
                                             (*N* = 963)                                                                                                                                                                                                                     
  ------------------------------------------ -------------- ----------------------------------------------- ----------------------------------------------- --------------------------------------------------------------------------- ------- -------- ------------------- --------
  Age, years                                 55.42          12.04                                           57.16                                           11.45                                                                       54.98   12.16    1.02 (1.00, 1.03)   0.0481

  Female, %                                  833            86.50%                                          175                                             90.21%                                                                      658     85.57%   NS                  

  White, %                                   816            84.74%                                          160                                             82.47%                                                                      656     85.31%   NS                  

                                                                                                                                                                                                                                                                             

  Disease duration, years                    11.04          9.47                                            11.29                                           9.55                                                                        10.98   9.46     NS                  

  Disease subsets, %                                                                                                                                                                                                                                     NS                  

   Limited disease                           563            59.26%                                          121                                             62.69%                                                                      442     58.39%                       

   Diffuse disease                           356            37.47%                                          69                                              35.75%                                                                      287     37.91%                       

   Sine scleroderma                          31             3.26%                                           3                                               1.55%                                                                       28      3.70%                        

                                                                                                                                                                                                                                                                             

  Modified Rodnan skin score (range, 0-51)   10.02          9.47                                            9.68                                            8.53                                                                        10.11   9.69     NS                  

  Swollen-joint count\                       0.91           3.34                                            1.07                                            4.26                                                                        0.87    3.07     NS                  
  (range, 0-28)                                                                                                                                                                                                                                                              

  Number of GI symptoms (range 0-14)         4.17           3.13                                            4.27                                            3.30                                                                        4.14    3.09     NS                  

  Inflammatory myositis, %                   103            11.48%                                          21                                              11.54%                                                                      82      11.47%   NS                  

  Thrombosis, %                              29             3.06%                                           7                                               3.65%                                                                       22      2.91%    NS                  

  Scleroderma renal crisis, %                42             4.44%                                           7                                               3.65%                                                                       35      4.64%    NS                  

  Interstitial lung disease, %               342            36.19%                                          85                                              44.27%                                                                      257     34.13%   1.53 (1.11, 2.12)   0.0091

  Pulmonary hypertension,%                   96             11.72%                                          26                                              15.38%                                                                      70      10.77%   NS                  

                                                                                                                                                                                                                                                                             

  Overlap with SLE, %                        30             3.19%                                           8                                               4.23%                                                                       22      2.93%    NS                  

  Overlap with Sjögren, %                    63             6.70%                                           18                                              9.52%                                                                       45      5.98%    NS                  

  Overlap with RA, %                         30             3.19%                                           8                                               4.23%                                                                       22      2.93%    NS                  

  Overlap with MCTD, %                       20             2.13%                                           7                                               3.70%                                                                       13      1.73%    NS                  

  Overlap with PM/DM, %                      36             3.83%                                           12                                              6.35%                                                                       24      3.19%    2.06 (1.01, 4.19)   0.0431

  Overlap syndrome, %                        143            15.18%                                          41                                              21.58%                                                                      102     13.56%   1.75 (1.17, 2.63)   0.0059
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; GI, gastrointestinal; MCTD, mixed connective tissue disease; NS, not significant; overlap syndrome, overlap with systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, mixed connective tissue disease, and/or polymyositis/dermatomyositis; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus.

Of the 963 SSc patients included in this study, 194 (20%) were positive for anti-Ro52/TRIM21 antibodies. This represents the second most common autoantibody in this cohort with anti-centromere, anti-RNA polymerase III, and anti-topoisomerase I antibodies present in approximately 35%, 19%, and 16% of the patients, respectively (Table [1](#T1){ref-type="table"}). Anti-Ro52/TRIM21 antibody-positive patients were more likely to be older (57.16 versus 54.98 years; *P*= 0.0481), to have interstitial lung disease (44% versus 34%; *P*= 0.0091), and to have overlap syndrome (22% versus 14%; *P*= 0.0059) compared with anti-Ro52/TRIM21 antibody-negative patients (Table [2](#T2){ref-type="table"}). In particular, anti-Ro52/TRIM21 antibody-positive patients were significantly more likely to have overlap with polymyositis/dermatomyositis (6% versus 3%; *P*= 0.0431) compared with anti-Ro52/TRIM21 antibody-negative patients. Also of note, two of 36 patients with polymyositis/dermatomyositis overlap had anti-Jo-1 antibodies (6%), and both of these had anti-Ro52/TRIM21 antibodies.

Disease severity measured by using the Medsger Disease Severity Scale was worse in two domains (range, 0 to 4): general (1.16 versus 0.82; *P*= 0.0061) and lung (1.56 versus 1.34; *P*= 0.0084) in anti-Ro52/TRIM21 antibody-positive compared with anti-Ro52/TRIM21 antibody-negative patients (Table [3](#T3){ref-type="table"}).

###### 

Association between Anti-Ro52/TRIM21 antibodies and disease severity (range, 0 to 4)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Whole group\   Anti-Ro52/TRIM21 antibody positive (*n*= 194)   Anti-Ro52/TRIM21 antibody negative (*n*= 769)   Odds ratio (95% CI) and *P*values (Anti-Ro52/TRIM21 positive vs negative)                                     
                                                           (*N* = 963)                                                                                                                                                                                                                  
  -------------------------------------------------------- -------------- ----------------------------------------------- ----------------------------------------------- --------------------------------------------------------------------------- ------ ------ ------------------- --------
  General                                                  0.89           1.22                                            1.16                                            1.41                                                                        0.82   1.16   1.23 (1.09, 1.39)   0.0061

  Skin                                                     1.25           0.68                                            1.23                                            0.60                                                                        1.25   0.69   NS                  

  Kidney                                                   0.12           0.61                                            0.12                                            0.61                                                                        0.12   0.61   NS                  

  Peripheral vascular                                      1.54           1.25                                            1.58                                            1.26                                                                        1.53   1.24   NS                  

  Joint/tendon                                             0.73           1.19                                            0.73                                            1.22                                                                        0.73   1.18   NS                  

  Muscle                                                   0.25           0.74                                            0.33                                            0.89                                                                        0.22   0.70   NS                  

  Gastrointestinal                                         1.95           0.82                                            2.01                                            0.78                                                                        1.93   0.82   NS                  

  Lung                                                     1.38           1.11                                            1.56                                            1.08                                                                        1.34   1.12   1.19 (1.04, 1.37)   0.0084

  Heart                                                    0.50           1.00                                            0.60                                            1.12                                                                        0.48   0.97   NS                  

                                                                                                                                                                                                                                                                                        

  Physician global assessments of severity (range, 0-10)   2.77           2.26                                            2.99                                            2.31                                                                        2.71   2.24   NS                  

  Patient global assessments of severity (range, 0-10)     3.64           2.61                                            3.66                                            2.67                                                                        3.63   2.60   NS                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; NS, not significant; SD, standard deviation.

Antibodies to Ro52/TRIM21 overlapped with many other autoantibodies (Table [4](#T4){ref-type="table"}). However, the association between anti-Ro52/TRIM21 antibodies and other autoantibodies differed according to antibody. Indeed, whereas 16% of the overall cohort had anti-topoisomerase I antibodies, only 10% of anti-Ro52/TRIM21-positive patients had anti-topoisomerase I antibodies (*P*= 0.0129), and the titers of anti-Ro52/TRIM21 antibodies were among the lowest measured (mean titer, 763.28 U/ml) in this subset of patients. Conversely, whereas 6% of the overall cohort had anti-Ro60 antibodies, 21% of anti-Ro52/TRIM21 antibody-positive patients were anti-Ro60 positive (*P*\< 0.0001), and the titers of anti-Ro52/TRIM21 antibodies were among the highest measured (mean titer, 5,530.66 U/ml). Similarly strong associations between anti-Ro52/TRIM21 antibodies and anti-Ro60 were noted between anti-Ro52/TRIM21 and anti-U1 RNP (*P*= 0.0066; mean titer, 2,099.45 U/ml), anti-SS-B/La (*P*\< 0.0001; mean titer, 6,003.88 U/ml), and anti-Jo-1 (*P*= 0.0171; mean titer, 4,412.83 U/ml), and to a lesser degree between anti-Ro52/TRIM21 and anti-CENP-B (*P*= 0.0372; mean titer, 1,098.86 U/ml) and anti-Sm (*P*= 0.0361; mean titer, 1,482.09 U/ml) antibodies.

###### 

Association between anti-Ro52/TRIM21 antibodies and other SSc-related autoantibodies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibody              Prevalence\   Anti-Ro52 antibody positive\   Anti-Ro52 antibody negative\   *P*values   Mean anti-Ro52/TRIM21 titer\                        
                        (*N* = 963)   (*n* = 194)                    (*n* = 769)                                (U/ml)                                              
  --------------------- ------------- ------------------------------ ------------------------------ ----------- ------------------------------ -------- ----------- ----------
  **Centromere**        334           34.76%                         78                             40.41%      256                            33.33%   NS          1,098.64

  **Topoisomerase I**   150           15.58%                         19                             9.79%       131                            17.04%   0.0129      763.28

  **RNApolIII**         144           18.58%                         23                             15.75%      121                            19.24%   NS          1,164.47

  **Pm/Scl**            53            6.84%                          10                             6.85%       43                             6.84%    NS          1,381.13

  **U1 RNP**            59            6.13%                          20                             10.31%      39                             5.07%    0.0066      2,099.45

  **CENP-B**            285           35.58%                         64                             42.95%      221                            33.90%   0.0372      1,098.86

  **CENP-A**            275           34.33%                         61                             40.94%      214                            32.82%   NS          1,019.93

  **Ro60**              53            5.50%                          40                             20.62%      13                             1.69%    \< 0.0001   5,530.66

  **SS-B/La**           26            2.70%                          18                             9.28%       8                              1.04%    \< 0.0001   6,003.88

  **Jo-1**              6             0.62%                          4                              2.06%       2                              0.26%    0.0171      4,412.83

  **Sm**                39            4.05%                          13                             6.70%       26                             3.38%    0.0361      1,482.09

  **Ribosomal P**       14            1.45%                          3                              1.55%       11                             1.43%    NS          2,088.14

  **Chromatin**         44            4.57%                          10                             5.15%       34                             4.42%    NS          1,162.30
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NS, not significant.

Finally, anti-Ro52/TRIM21 antibody titers were significantly higher in patients with compared to patients without overlap syndrome (mean titer, 1,330.40 versus 1,105.05 U/ml, respectively; *P*= 0.0026). A strong trend was noted toward higher titers in patients with compared to those without interstitial lung disease (mean titer, 1,542.65 versus 938.11 U/ml, respectively; *P*= 0.06).

Discussion
==========

In this large, multicenter cohort study, we found that anti-Ro52/TRIM21 antibodies were present in 20% of 963 patients, making them the second most common autoantibodies in this SSc cohort, and they overlapped with all of the major SSc-related antibodies. In addition, in this cohort of SSc patients, we found strong suggestions of an association between anti-Ro52/TRIM21 antibodies and interstitial lung disease and overlap syndrome.

Several studies have demonstrated that anti-Ro52/TRIM21 antibodies are present in several systemic autoimmune rheumatic diseases \[[@B11],[@B28]-[@B31]\]. In particular, anti-Ro52 antibodies are frequently found in the inflammatory myositides, often in the presence of anti-Jo1 and interstitial lung disease \[[@B32]-[@B34]\].

The largest study to date of anti-Ro52 in SSc (measured using an ELISA), a recent British report of 1,010 SSc patients, found an overall frequency of anti-Ro52/TRIM21 antibodies of 27% \[[@B35]\]. We have shown that the ALBIA anti-Ro52/TRIM21 antibody has high concordance (\> 95%) with an anti-Ro52/TRIM21 ELISA (unpublished data), suggesting that the higher prevalence in the British study is not related to interlaboratory assay variation. Although the majority of our patients were White (85%), the British study did not report on the ethnic profile or disease duration of their patients. The British study also showed that anti-Ro52/TRIM21 antibodies overlapped with all of the major SSc-related antibodies, including anti-centromere, anti-topoisomerase I, and anti-RNA polymerase III antibodies (in their study, at frequencies of 28%, 19%, and 25%, respectively). In addition, they confirmed that anti-Ro52/TRIM21 antibody titers were particularly elevated in patients with anti-Ro60 and anti-aminoacyl-tRNA synthetase antibodies (of whom four were anti-Jo1 positive). Although the authors did not present actual clinical data, they nevertheless concluded that Ro52/TRIM21 antibodies appeared to be general serum markers with limited linkage to distinct clinical manifestations of SSc.

In another recent study by Ghillani *et al.*\[[@B36]\], 155 patients positive for anti-Ro52/TRIM21 antibodies but negative for anti-Ro60 antibodies were analyzed. The authors found that anti-Ro52/TRIM21 antibodies were commonly found in the presence of other autoantibodies (in particular, Sm, chromatin, Jo-1, and CENP-B) and that 73% of patients had an autoimmune disease (in particular, polymyositis/dermatomyositis, SjS, SSc, and autoimmune hepatitis). Interestingly, the authors reported that the prevalence of pulmonary disease was particularly high among anti-Ro52/TRIM21 antibody-positive patients (22% of patients), including seven of 11 patients with SSc.

A recent article from the German Network for Systemic Sclerosis specifically examined the clinical correlates of a number of autoantibodies in SSc, including Ro52 \[[@B37]\]. They found that the prevalence anti-Ro52 antibody in their cohort (*N*= 863) was 21.7% and that 25% of patients with overlap syndrome were positive for anti-Ro52 antibody. Although they did not find any statistically significant association between anti-Ro52 antibodies and specific clinical features, it is interesting to note that their point estimate for an association with pulmonary fibrosis was 1.3. They also reported a statistically significant twofold increase in the rate of pulmonary fibrosis among patients who had anti-Ro60 antibodies (odds ratio (OR), 2.20; 95% confidence interval (CI), 1.29 to 3.75; *P*= 0.004). In our study, the rate of interstitial lung disease among anti-Ro52/TRIM21 antibody-positive patients was significantly increased by 50% compared with anti-Ro52/TRIM21 antibody-negative patients (OR, 1.53; 95% CI, 1.11 to 2.12; *P*= 0.0091). In addition, the association between anti-Ro60 antibody and interstitial lung disease was increased almost threefold (OR, 2.86; 95% CI, 1.62 to 5.04; *P*= 0.0002; data not shown).

Thus, the findings of our study are generally consistent with the current literature. In addition to confirming the serologic associations between anti-Ro52/TRIM21 antibodies and other autoantibodies, we found important associations between anti-Ro52/TRIM21 antibodies, interstitial lung disease, and overlap syndrome.

Overlap syndrome is highly prevalent among patients with systemic autoimmune rheumatic diseases and is thought to suggest that these diseases share similar immunogenetic mechanisms \[[@B38]-[@B40]\]. The concept of \"overlap\" syndrome in SSc, however, remains elusive, with some of the common manifestations of the disease, including sicca and myositis, being possibly related to SSc itself or to a separate autoimmune disease. We believe that serologic associations could help to shape a better definition of overlap in SSc, and that anti-Ro52/TRIM21 antibodies have the potential to be good biomarkers of overlap in this disease.

The Ro52 gene has been mapped to the end of the short arm of human chromosome 11 \[[@B29]\]. Evidence suggests that this chromosome segment may harbor genes important in the development and progression of solid tumors. Given this, we reviewed our data and found that 12.04% of anti-Ro52/TRIM21 antibody-positive patients compared with 7.24% of anti-Ro52/TRIM21 antibody-negative patients had a physician-reported history of malignancy (*P*= 0.03). These data have yet to be validated through chart review and remain preliminary.

Our understanding of how a number of SSc-related autoantibodies are generated (for example, through apoptosis, microbody release, molecular mimicry, or other mechanisms) and of their role in the pathogenesis of disease has increased remarkably over the past two decades (reviewed in \[[@B41],[@B42]\]). The recently reported mechanism of intracellular immunity mediated by Ro52/TRIM21 in a cellular model of adenovirus infection has opened new perspectives for studying the effects of autoantibodies once they are inside cells \[[@B10]\]. The association between Ro52/TRIM21 and other proteins such as TRIB2, implicated in driving tumorigenesis \[[@B43]\], with Fas-associated death domain (FADD) and negatively regulating the IFN-α pathway in response to viral infection \[[@B44]\] and its interaction with virus-like particles and high-affinity IgG receptors affecting the intracellular fate of viruses, including degradation by the proteasomes \[[@B10],[@B45],[@B46]\] may provide important insights into the generation of the autoantibody response and its perpetuation in SSc. Further, the association of anti-Ro52/TRIM21 antibodies with cytokine responses such as IFN-α \[[@B44]\] and Toll-like receptor-mediated NF-κB activation \[[@B47]\] provides some insight into its regulation of cytokine responses. Thus, despite clearer understanding of the physiological function of Ro52/TRIM21 *in vitro*, it is still unclear how anti-Ro52/TRIM21 antibodies arise, particularly *in vivo*, and whether they have any pathologic significance in SSc or other systemic autoimmune rheumatic diseases. Of note, though, is the fact that anti-Ro52/TRIM21 antibodies are seen across a number of autoimmune diseases with significant prevalence (ranging from 1% to 63%) but are only rarely seen in normal controls; this suggests that they are markers of autoimmune dysfunction \[[@B29]\]. Further studies will be needed to shed greater insight into their precise role in autoimmune diseases.

Conclusions
===========

We believe that this study makes a significant contribution to the literature on the clinical significance of anti-Ro52/TRIM21 antibodies. Although consistent data show that SSc-specific antibodies are generally mutually exclusive, it is important to appreciate that a multiplicity of other nonspecific markers of humoral immune response exist in SSc, with Ro52/TRIM21 being one of the most common of these. In addition, Ro52/TRIM21 appears to have distinct clinical associations in SSc, in particular with interstitial lung disease and overlap syndrome. These data suggest that Ro52/TRIM21 may be of both diagnostic and prognostic importance in SSc.
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